• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

作者信息

Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios C H, Bergh J, Biganzoli L, Blackwell K L, Cardoso M J, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano S H, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin U N, Mayer M, Merjaver S D, Nordström E B, Pagani O, Partridge A, Penault-Llorca F, Piccart M J, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E

机构信息

European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal.

European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland.

出版信息

Ann Oncol. 2014 Oct;25(10):1871-1888. doi: 10.1093/annonc/mdu385. Epub 2014 Sep 18.

DOI:10.1093/annonc/mdu385
PMID:25234545
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4176456/
Abstract
摘要

相似文献

1
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.欧洲肿瘤内科学会（ESO）-欧洲医学肿瘤学会（ESMO）晚期乳腺癌第二版国际共识指南（ABC2）†
Ann Oncol. 2014 Oct;25(10):1871-1888. doi: 10.1093/annonc/mdu385. Epub 2014 Sep 18.
2
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).欧洲肿瘤内科学会（ESO）-欧洲医学肿瘤学会（ESMO）晚期乳腺癌第二版国际共识指南（ABC2）
Breast. 2014 Oct;23(5):489-502. doi: 10.1016/j.breast.2014.08.009. Epub 2014 Sep 20.
3
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.《第四届欧洲中学教育阶段（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 4）》† 。
Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192.
4
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).第五届欧洲中学教育阶段（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 5）
Ann Oncol. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. Epub 2020 Sep 23.
5
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).ESO-ESMO 第 3 版年轻女性乳腺癌国际共识指南（BCY3）。
Breast. 2017 Oct;35:203-217. doi: 10.1016/j.breast.2017.07.017. Epub 2017 Aug 17.
6
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).第三届欧洲中学教育阶段（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 3）
Breast. 2017 Feb;31:244-259. doi: 10.1016/j.breast.2016.10.001. Epub 2016 Dec 5.
7
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).第三届欧洲中学教育阶段（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 3）
Ann Oncol. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544.
8
ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4).ESO-ESMO 4 版年轻女性乳腺癌国际共识指南（BCY4）。
Ann Oncol. 2020 Jun;31(6):674-696. doi: 10.1016/j.annonc.2020.03.284. Epub 2020 Mar 19.
9
ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5).ESO-ESMO 第五次国际年轻女性乳腺癌共识指南（BCY5）。
Ann Oncol. 2022 Nov;33(11):1097-1118. doi: 10.1016/j.annonc.2022.07.007. Epub 2022 Aug 4.
10
Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.治疗绝经前亚洲女性的 HR+/HER2- 乳腺癌：亚洲乳腺癌合作组 2019 年关于卵巢抑制的共识和立场。
Breast Cancer Res Treat. 2019 Oct;177(3):549-559. doi: 10.1007/s10549-019-05318-5. Epub 2019 Jul 4.

引用本文的文献

1
Real-world treatment patterns and outcomes of patients with hormone receptor-positive/HER2-low metastatic breast cancer treated with chemotherapy.接受化疗的激素受体阳性/HER2低表达转移性乳腺癌患者的真实世界治疗模式和结局
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf106.
2
Survival Values of Iraqi Male Breast Cancer.伊拉克男性乳腺癌的生存价值
Asian Pac J Cancer Prev. 2025 Apr 1;26(4):1379-1384. doi: 10.31557/APJCP.2025.26.4.1379.
3
Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.在先前内分泌治疗后病情进展的HR+/HER2-局部晚期或转移性乳腺癌患者中使用来罗西利布联合氟维司群：LEONARDA-1一项III期随机试验
Nat Commun. 2025 Jan 16;16(1):716. doi: 10.1038/s41467-025-56096-2.
4
Evaluation of CDK4/6 inhibitors in first-line in symptomatic and asymptomatic patients with metastatic breast cancer.CDK4/6抑制剂在有症状和无症状转移性乳腺癌一线治疗中的评估。
Future Oncol. 2024 Dec;20(40):3443-3450. doi: 10.1080/14796694.2024.2432850. Epub 2024 Nov 26.
5
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer.一项关于哌柏西利联合他莫昔芬治疗激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌患者的3期研究（PATHWAY研究）。
NPJ Breast Cancer. 2024 Aug 22;10(1):76. doi: 10.1038/s41523-024-00684-w.
6
Endophytic fungi: A future prospect for breast cancer therapeutics and drug development.内生真菌：乳腺癌治疗与药物开发的未来前景
Heliyon. 2024 Jul 4;10(13):e33995. doi: 10.1016/j.heliyon.2024.e33995. eCollection 2024 Jul 15.
7
Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy.探索RANK通路抑制在晚期乳腺癌中的临床影响：来自一项关于CDK4/6抑制剂和抗吸收治疗的回顾性研究的见解
Cureus. 2024 Jun 28;16(6):e63362. doi: 10.7759/cureus.63362. eCollection 2024 Jun.
8
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial.使用二甲双胍预防HR+/HER2-/-突变的晚期乳腺癌中与阿哌利西布相关的高血糖（METALLICA）：一项多中心、开放标签、单臂、2期试验。
EClinicalMedicine. 2024 Apr 11;71:102520. doi: 10.1016/j.eclinm.2024.102520. eCollection 2024 May.
9
Clinical Review on the Management of Breast Cancer Visceral Crisis.乳腺癌内脏危象管理的临床综述
Biomedicines. 2023 Apr 3;11(4):1083. doi: 10.3390/biomedicines11041083.
10
Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.铜死亡相关 ceRNA 网络的综合分析提示 ER 阳性乳腺癌潜在的内分泌治疗抵抗机制。
BMC Med Genomics. 2023 May 5;16(1):96. doi: 10.1186/s12920-023-01511-0.

本文引用的文献

1
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.依维莫司联合依西美坦治疗激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌：BOLERO-2研究的总生存结果†
Ann Oncol. 2014 Dec;25(12):2357-2362. doi: 10.1093/annonc/mdu456. Epub 2014 Sep 17.
2
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).在II至III期三阴性乳腺癌中，于每周一次的新辅助紫杉醇治疗后加用卡铂和/或贝伐单抗，随后进行剂量密集型阿霉素和环磷酰胺治疗，对病理完全缓解率的影响：CALGB 40603（联盟）研究
J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4.
3
Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program.患者导航能否改善推荐的乳腺癌护理的接受情况？来自国家患者导航研究计划的证据。
J Clin Oncol. 2014 Sep 1;32(25):2758-64. doi: 10.1200/JCO.2013.53.6037. Epub 2014 Jul 28.
4
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.新辅助卡铂治疗三阴性和 HER2 阳性早期乳腺癌患者（GeparSixto；GBG 66）：一项随机 2 期试验。
Lancet Oncol. 2014 Jun;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30.
5
First international consensus guidelines for breast cancer in young women (BCY1).《年轻女性乳腺癌国际共识指南（第一版，BCY1）》
Breast. 2014 Jun;23(3):209-20. doi: 10.1016/j.breast.2014.03.011. Epub 2014 Apr 24.
6
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial.晚期癌症患者的早期姑息治疗：一项集群随机对照试验。
Lancet. 2014 May 17;383(9930):1721-30. doi: 10.1016/S0140-6736(13)62416-2. Epub 2014 Feb 19.
7
The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.铂类药物作为三阴性乳腺癌新辅助化疗的价值：一项系统评价和荟萃分析。
Breast Cancer Res Treat. 2014 Apr;144(2):223-32. doi: 10.1007/s10549-014-2876-z. Epub 2014 Feb 21.
8
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma.1051 例浸润性小叶乳腺癌患者新辅助化疗的反应和预后。
Breast Cancer Res Treat. 2014 Feb;144(1):153-62. doi: 10.1007/s10549-014-2861-6. Epub 2014 Feb 7.
9
Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment.使用立体定向体部放疗（SBRT）技术进行胸部再照射作为首次或第二次治疗疗程。
Radiother Oncol. 2014 Mar;110(3):505-10. doi: 10.1016/j.radonc.2013.11.017. Epub 2014 Jan 17.
10
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.乳腺癌局部区域性孤立复发的化疗（CALOR）：一项随机试验。
Lancet Oncol. 2014 Feb;15(2):156-63. doi: 10.1016/S1470-2045(13)70589-8. Epub 2014 Jan 16.